diamedica.com - DMAC Total Company Value-to-Revenue Ratio

Public company logo of diamedica.com (DMAC)

Effective distribution of nephrological products ensures high margins for DiaMedica Therapeutics (DMAC). This EV/Sales chart visualizes this trend, where the 0.00 metric indicates the status of the current valuation. Growth potential is based on a global patent for post-stroke therapy. Meanwhile, management is focused on clinical trials, awaiting decisions from monitoring committees to confirm shareholder confidence.

DMAC DiaMedica Therapeutics Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

DiaMedica Therapeutics - analytical breakdowns and key metrics (DMAC)

- share price and consensus valuation forecast:
- money and cash flow information:
Fundamental company valuation:DMAC (DiaMedica Therapeutics)
Core merchandise of DiaMedica Corp

For DiaMedica Therapeutics (DMAC), which relies on scientific authority in the development of stroke treatments, revenue-based valuation is critically important. By analyzing changes in the EV/Sales ratio, an investor can see the relationship between the total enterprise value and its sales, excluding debt load. This metric allows for the identification of asset overvaluation or operational stagnation. Excessively low values may indicate a systemic business decline. The indicator's trend reflects market expectations regarding the results of current clinical trials.